Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280649 | 0.89 | TLR7 (0.53) | TLR7TLR8 | |
| SCHEMBL5129268 | 0.88 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL5124550 | 0.87 | TLR7 (0.54) | TLR7TLR8 | |
| Hydrochloric Acid SCHEMBL6280065 | 0.86 | TLR7 (0.53) | TLR7TLR8 | |
| Acetic Acid SCHEMBL28392158 | 0.86 | TLR7 (0.67) | TLR7TLR8 | |
| SCHEMBL6280560 | 0.83 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL5117023 | 0.82 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL20806172 | 0.81 | TLR7 (0.69) | TLR7TLR8 | |
| Acetic Acid SCHEMBL5128218 | 0.80 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL5618407 | 0.79 | TLR7 (0.72) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| WO-2005123079-A2 | UREA SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | IL2, EIF2AK2, IL4 | TLR7 215/4885TLR8 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.